Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients

Inclusion criteria

MS patients:

• subjects: 18 Years to 60 Years
• with a confirmed and documented MS diagnosis, per the 2010 Revised McDonald criteria
• with or without MS maintenance and/or symptomatic treatment, if MS maintenance and/or symptomatic treatment: stable for the past 6 months before enrolment (Centrally acting antalgics, antidepressant or neuroleptic treatment are authorized but shall not be modified in the past 2 months before enrolment)
• with an EDSS [0;7] in the past 6 months before enrolment
• with an EDSS [0;7] in the past 6 months before enrolment
• with no evidence of EDSS score change since the last measure available
• with no evidence of relapse in the past 6 months before enrolment
• enrolled in or benefiting of a Social Security program
• who have read the information sheet and signed the informed consent form

Healthy volunteers:

• subjects: 18 Years to 60 Years
• with no evidence of walk limitation (as per clinician's judgment) nor walking aid
• no personal and familial history of inflammatory disease (e.g. rheumatoid arthritis) or multiple sclerosis
• matched to the sociodemographic characteristics of MS patients sample (age, sex, height, weight, education)
• enrolled in or benefiting of a Social Security program
• who have read the information sheet and signed the informed consent form

Non-Inclusion Criteria:

MS patients and Healthy volunteers:

• Participants wearing pacemakers, implantable defibrillators, or hearing aids
• Inability to use their right hand for the Coordination test (MCT)
• Evidence of neurologic or psychiatric disorder other than MS, including but not limited to major head trauma, seizures or systemic medical diseases that are likely to affect cognitive functioning
• Evolutive rheumatology disease
• Any vision (ex. short-sightedness (-6; +6); congenital dyschromatopsia and glaucoma) or hearing conditions that could influence the performing of the tests
• Omission of the usual visual and/or walking aids if it's usually needed
• Acute asthenia (score>7 on a visual analogic scale)
• Systemic corticosteroid treatment in the past 30 days before enrolment
• Intramuscular botulinic toxin injection in the past 4 months before enrolment
• Change in centrally acting antalgic, antidepressant or neuroleptic treatment in the past 2 months before enrolment
• Rehabilitation in the past 6 months before enrolment
• Pregnant and nursing women - Person under guardianship or curatorship
• Bedridden patients or patients with a daily activity of less than 2 hours per day
• Inability to use a mobile application
• Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
• Participation to another study Healthy volunteers who will not match the sociodemographic characteristics of MS patients will not be included in the study.

Exclusion criteria

• Patient experiencing a relapse once enrolled in the study
• Patient with a maintenance and symptomatic MS treatment modification
• Use of centrally acting antalgics, antidepressant or neuroleptic once enrolled in the study
• Substance or/and alcohol abuse that could influence performance on the tests between inclusion and follow-up visits (clinician's judgement)
• Omission or change in the usual visual and/or walking aids
• Acute asthenia (score>7 on a visual analogic scale) at the follow-up visit.